ABSTRACT
The incidence of chronic pain is high in the general population and it is closely related to anxiety disorders, which promote negative effects on the quality of life. The cannabinoid system has essential participation in the pain sensitivity circuit. In this perspective, cannabidiol (CBD) is considered a promising strategy for treating neuropathic pain. Our study aimed to evaluate the effects of sub-chronic systemic treatment with CBD (0.3, 3, 10, or 30 mg/kg, i.p.) in male in rats submitted to chronic constriction injury of the sciatic nerve (CCI) or not (SHAM) and assessed in nociceptive tests (von Frey, acetone, and hot plate, three days CBD's treatment) and in the open field test (OFT, two days CBD's treatment). We performed a screening immunoreactivity of CB1 and TRPV1 receptors in cortical and limbic regions tissues, which were collected after 1.5 h of behavioral tests on the 24th experimental day. This study presents a dose-response curve to understand better the effects of low doses (3 mg/kg) on CBD's antiallodynic and anxiolytic effects. Also, low doses of CBD were able to (1) reverse mechanical and thermal allodynia (cold) and hyperalgesia, (2) reverse anxious behaviors (reduction of the % of grooming and freezing time, and increase of the % of center time in the OFT) induced by chronic pain. The peripheral neuropathy promoted the increase in the expression of CB1 and TRPV1 receptors in the anterior cingulate cortex (ACC), anterior insular cortex (AIC), basolateral amygdala (BLA), dorsal hippocampus (DH), and ventral hippocampus (VH). CBD potentiated this effect in the ACC, AIC, BLA, DH, and VH regions. These results provide substantial evidence of the role of the ACC-AIC-BLA corticolimbic circuit, and BLA-VH for pain regulation. These results can be clinically relevant since they contribute to the evidence of CBD's beneficial effects on treating chronic pain and associated comorbidities such as anxiety.
Subject(s)
Anxiety/drug therapy , Cannabidiol/therapeutic use , Hyperalgesia/drug therapy , Neuralgia/drug therapy , Receptor, Cannabinoid, CB1/drug effects , TRPV Cation Channels/drug effects , Animals , Anxiety/psychology , Cerebral Cortex/metabolism , Hippocampus/metabolism , Hot Temperature , Limbic System/drug effects , Male , Nerve Net/drug effects , Neuralgia/metabolism , Neuralgia/psychology , Pain Measurement/drug effects , Physical Stimulation , Rats , Rats, Wistar , Sciatica/drug therapyABSTRACT
STUDY DESIGN: Systematic with meta-analysis OBJECTIVES.: The aim of this study was to investigate the efficacy and safety of epidural corticosteroid injections compared with placebo injection in reducing leg pain and disability in patients with sciatica. SUMMARY OF BACKGROUND DATA: Conservative treatments, including pharmacological and nonpharmacological treatments, are typically the first treatment options for sciatica but the evidence to support their use is limited. The overall quality of evidence found by previous systematic reviews varies between moderate and high, which suggests that future trials may change the conclusions. New placebo-controlled randomized trials have been published recently which highlights the importance of an updated systematic review. METHODS: The searches were performed without language restrictions in the following databases from 2012 to 25 September 2019: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, PubMed, Embase, CINAHL, PsycINFO, International Pharmaceutical Abstracts, and trial registers. We included placebo-controlled randomized trials investigating epidural corticosteroid injections in patients with sciatica. The primary outcomes were leg pain intensity and disability. The secondary outcomes were adverse events, overall pain, and back pain intensity. We grouped similar trials according to outcome measures and their respective follow-up time points. Short-term follow-up (>2 weeks but ≤3 months) was considered the primary follow-up time point due to the expected mechanism of action of epidural corticosteroid injection. Weighted mean differences (MDs) and risk ratios (RRs) with their respective 95% confidence intervals (CIs) were estimated. We assessed the overall quality of evidence using the GRADE approach and conducted the analyses using random effects. RESULTS: We included 25 clinical trials (from 29 publications) providing data for a total of 2470 participants with sciatica, an increase of six trials when compared to the previous review. Epidural corticosteroid injections were probably more effective than placebo in reducing short-term leg pain (MD -4.93, 95% CI -8.77 to -1.09 on a 0-100 scale), short-term disability (MD -4.18, 95% CI: -6.04 to -2.17 on a 0-100 scale) and may be slightly more effective in reducing short-term overall pain (MD -9.35, 95% CI -14.05 to -4.65 on a 0-100 scale). There were mostly minor adverse events (i.e., without hospitalization) after epidural corticosteroid injections and placebo injections without difference between groups (RR 1.14, 95% CI: 0.91-1.42). The quality of evidence was at best moderate mostly due to problems with trial design and inconsistency. CONCLUSION: A review of 25 placebo-controlled trials provides moderate-quality evidence that epidural corticosteroid injections are effective, although the effects are small and short-term. There is uncertainty on safety due to very low-quality evidence. LEVEL OF EVIDENCE: 1.
Subject(s)
Adrenal Cortex Hormones/administration & dosage , Pain Measurement/drug effects , Pain/drug therapy , Sciatica/drug therapy , Humans , Injections, Epidural , Pain/diagnosis , Pain Measurement/methods , Randomized Controlled Trials as Topic/methods , Sciatica/diagnosisABSTRACT
La lumbociatalgia es un problema clínico común, que en la mayoría de los casos se autolimita y se puede tratar en forma conservadora, usando medidas no farmacológicas y analgésicos como paracetamol o los antiinflamatorios no esteroi-deos. Otro medicamento muy utilizado en nuestro medio es la pregabalina, a pesar de que no se encuentra aprobada para dicha indicación. En este trabajo, el autor se pregunta acerca de la utilidad clínica de la pregabalina y luego de hacer una búsqueda bibliográfica sobre la evidencia más actualizada y de mejor calidad acerca del tema, concluye que no es efectiva para lumbociatalgia y que se acompaña de efectos adversos significativos. Esto coincide con las recomenda-ciones de las guías internacionales, que en su mayoría desaconsejan el uso de anticonvulsivantes para la lumbalgia. (AU)
Sciatica is a common clinical situation, in most cases self-limited and which can be managed conservatively with nonpharmaco-logic treatment and analgesics, such as paracetamol or nonsteroidal anti-inflammatory drugs. Pregabalin is also commonly used, despite not being approved for this indication. In this article, the author queries about the clinical usefulness of pregabalin, and after carrying out a bibliographic search of the most recent and best-quality evidence, concludes that it is not effective in sciatica while it causes significant adverse effects. This is in line with the recommendations of most international guidelines,that do not recommend the use of anticonvulsivants drugs for the treatment of lumbalgia. (AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Young Adult , Sciatica/drug therapy , Low Back Pain/drug therapy , Evidence-Based Practice/trends , Pregabalin/adverse effects , Anticonvulsants/adverse effects , Sciatica/surgery , Sciatica/therapy , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Low Back Pain/surgery , Low Back Pain/therapy , Pregabalin/administration & dosage , Pregabalin/therapeutic use , Analgesics/therapeutic use , Nerve Block/trendsSubject(s)
Sciatica/drug therapy , Acetaminophen/therapeutic use , Analgesics, Opioid/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Anticonvulsants/therapeutic use , Antidepressive Agents/therapeutic use , Benzodiazepines/therapeutic use , Biological Products/therapeutic use , Clinical Decision-Making , Diagnosis, Differential , Evidence-Based Medicine , Glucocorticoids/therapeutic use , Humans , Low Back Pain/diagnosis , Randomized Controlled Trials as Topic , Sciatica/diagnosisSubject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Young Adult , Sciatica/drug therapy , Pregabalin/therapeutic use , Analgesics/therapeutic use , Quality of Life , Sciatica/classification , Pain Measurement , Randomized Controlled Trials as Topic , Treatment Failure , Back Pain/classification , Disability Evaluation , Dizziness/chemically induced , Pregabalin/administration & dosage , Pregabalin/adverse effects , Analgesics/administration & dosage , Analgesics/adverse effectsABSTRACT
The objective of this study was to describe a perisciatic ultrasound-guided infiltration technique for treatment of deep gluteal syndrome and to report its preliminary clinical results. A mixture of saline (20 mL), a local anesthetic (4 mL), and a corticosteroid solution (1 mL) was infiltrated in the perisciatic region between the gluteus maximus and pelvitrochanteric muscles. Relative pain relief was achieved in 73.7% of the patients, with average preprocedural and postprocedural visual analog scale scores of 8.3 and 2.8, respectively. Fifty percent of patients reported recurrence of discomfort, and the average duration of the therapeutic effect in these patients was 5.3 weeks.
Subject(s)
Anesthesia, Local/methods , Anesthetics, Local/administration & dosage , Piriformis Muscle Syndrome/diagnostic imaging , Piriformis Muscle Syndrome/drug therapy , Sciatic Nerve/ultrastructure , Sciatica/diagnostic imaging , Sciatica/drug therapy , Ultrasonography, Interventional/methods , Adult , Female , Humans , Male , Pain Measurement/drug effects , Pilot Projects , Reproducibility of Results , Sciatic Nerve/drug effects , Sensitivity and Specificity , Treatment OutcomeABSTRACT
The aim of the present study is to investigate the ameliorative potential of ethanolic extract of whole plant of Vernonia cinerea in the chronic constriction injury (CCI) of sciatic nerve induced neuropathic pain in rats. Behavioral parameters such as a hot plate, acetone drop, paw pressure, Von Frey hair and tail immersion tests were performed to assess the degree of thermal, chemical and mechanical hyperalgesia and allodynia. Biochemical changes in sciatic nerve tissue were ruled out by estimating thiobarbituric acid reactive substances (TBARS), reduced glutathione (GSH) and total calcium levels. Ethanolic extract of Vernonia cinerea and pregabalin were administered for 14 consecutive days starting from the day of surgery. CCI of sciatic nerve has been shown to induce significant changes in behavioral, biochemical and histopathological assessments when compared to the sham control group. Vernonia cinerea attenuated in a dose dependent manner the above pathological changes induced by CCI of the sciatic nerve, which is similar to attenuation of the pregabalin pretreated group. The ameliorating effect of ethanolic extract of Vernonia cinerea against CCI of sciatic nerve induced neuropathic pain may be due to the presence of flavonoids and this effect is attributed to anti-oxidative, neuroprotective and calcium channel modulator actions of these compounds.
Subject(s)
Plant Extracts/therapeutic use , Sciatica/drug therapy , Vernonia/chemistry , Animals , Constriction , Disease Models, Animal , Female , Male , Pain Measurement , Rats, Wistar , Sciatica/etiology , Time FactorsABSTRACT
UNLABELLED: The effect of long-term administration of imipramine, a tricyclic antidepressant, on the phosphorylation status of cyclic adenosine monophosphate-responsive element-binding protein (CREB), mitogen-activated protein kinase family members, and phospholipase γ-1 (PLCγ-1) was investigated in the dorsal horn of the spinal cord following peripheral nerve lesion. Nerve injury induced an ipsilateral long-lasting increased phosphorylation of CREB and PLCγ-1 but not extracellular signal-regulated kinase (ERK1,2), p38, and c-Jun N-terminal kinase. Daily administration of imipramine (5, 10, or 30 mg/kg) for 21 days progressively reduced both tactile-induced neuropathic pain hypersensitivity and thermal hyperalgesia. After withdrawal of treatment, the antinociceptive effect of imipramine was gradually abolished but still remained for at least 3 weeks. Conversely, no analgesic effect was observed with short-term imipramine treatment. Moreover, imipramine therapy reversed nerve injury-induced CREB and PLCγ-1 phosphorylation but had no effect on ERK1,2, p38, and c-Jun N-terminal kinase activity. These results indicate that long-term administration of imipramine may prevent some of the harmful changes in the spinal cord dorsal horn following nerve injury. However, imipramine analgesic effect takes time to develop and mature, which might explain in part why the clinical analgesic effect of tricyclic antidepressants develops with a delay after the beginning of treatment. Our data also provide evidence that prolonged imipramine treatment may induce antinociception in neuropathic pain conditions because of its action on the PLCγ-1/CREB-signaling pathway. PERSPECTIVE: This article demonstrates that long-term treatment with imipramine reverses some of the marked effects induced by peripheral nerve injury in the spinal dorsal horn that contribute to long-term maintenance of sensory disorder, providing a new view to the mechanisms of action of these drugs.
Subject(s)
Antidepressive Agents/therapeutic use , Cyclic AMP Response Element-Binding Protein/metabolism , Neuralgia/drug therapy , Neuralgia/metabolism , Phospholipase C gamma/metabolism , Posterior Horn Cells/metabolism , Animals , Antidepressive Agents, Tricyclic/therapeutic use , Behavior, Animal/drug effects , Blotting, Western , Imipramine/therapeutic use , Immunohistochemistry , MAP Kinase Signaling System/drug effects , Male , Mice , Mice, Inbred BALB C , Mitogen-Activated Protein Kinases/metabolism , Pain Measurement/drug effects , Phosphorylation/drug effects , Sciatica/drug therapy , Sciatica/pathology , p38 Mitogen-Activated Protein Kinases/metabolismABSTRACT
BACKGROUND AND OBJECTIVES: Lumbar epidural technique has been used in the treatment of lombosciatalgia since 1953. In most cases, methylprednisolone is used along with a local anesthetic, and it is not known whether the isolated use of methylprednisolone is equally effective in relieving symptoms. The objective of this study was to compare the efficacy of two different solutions--methylprednisolone with saline and methylprednisolone with levobupivacaine injected in the epidural space to heal lombosciatalgia secondary to lumbar herniated disk. METHODS: Sixty individuals ASA I and II, of both genders, ages 18 to 65 years participated in this randomized, double-blind study over a period of one year. They underwent interlaminar lumbar epidural analgesia without radioscopic control to heal a lombosciatalgia and they were divided into two groups: G-M (methylprednisolone + saline) and G-M + L (methylprednisolone + levobupivacaine + saline) both at a volume of 10 mL. Diagnosis was based on history, physical exam, and imaging exam (MRI). The Visual Analogue Scale (VAS) was applied in a total of two blockades, 15 days apart. RESULTS: A reduction in pain severity was observed in the methylprednisolone-levobupivacaine group, but without statistical significance. CONCLUSIONS: The analgesic efficacy of the G-M + L solution was superior to that of the G-M solution in the treatment of discal lombosciatalgia regarding the shorter time to onset of analgesia, but this was not significant at the time of discharge, and both solutions were effective in the treatment of discal lombosciatalgia.
Subject(s)
Anesthesia, Epidural , Anesthetics, Local/therapeutic use , Anti-Inflammatory Agents/administration & dosage , Methylprednisolone/therapeutic use , Sciatica/drug therapy , Adolescent , Adult , Aged , Anesthesia, Epidural/methods , Anesthetics, Local/administration & dosage , Bupivacaine/administration & dosage , Bupivacaine/analogs & derivatives , Bupivacaine/therapeutic use , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Intervertebral Disc Displacement/complications , Levobupivacaine , Lumbosacral Region , Male , Methylprednisolone/administration & dosage , Middle Aged , Sciatica/etiology , Young AdultABSTRACT
RATIONALE: Neuropathic pain is associated with significant co-morbidities, including depression, which impact considerably on the overall patient experience. Pain co-morbidity symptoms are rarely assessed in animal models of neuropathic pain. Neuropathic pain is characterized by hyperexcitability within nociceptive pathways and remains difficult to treat with standard analgesics. OBJECTIVES: The present study determined the effect of bis selenide and conventional antidepressants (fluoxetine, amitriptyline, and bupropion) on neuropathic pain using mechanical allodynic and on depressive-like behavior. METHODS: Male mice were subjected to chronic constriction injury (CCI) or sham surgery and were assessed on day 14 after operation. Mice received oral treatment with bis selenide (1-5 mg/kg), fluoxetine, amitriptyline, or bupropion (10-30 mg/kg). The response frequency to mechanical allodynia in mice was measured with von Frey hairs. Mice were evaluated in the forced swimming test (FST) test for depression-like behavior. RESULTS: The CCI procedure produced mechanical allodynia and increased depressive-like behavior in the FST. All of the drugs produced antiallodynic effects in CCI mice and produced antidepressant effects in control mice without altering locomotor activity. In CCI animals, however, only the amitriptyline and bis selenide treatments significantly reduced immobility in the FST. CONCLUSION: These data demonstrate an important dissociation between the antiallodynic and antidepressant effects in mice when tested in a model of neuropathic pain. Depressive behavior in CCI mice was reversed by bis selenide and amitriptyline but not by the conventional antidepressants fluoxetine and buproprion. Bis selenide was more potent than the other drugs tested for antidepressant-like and antiallodynic effects in mice.
Subject(s)
Amitriptyline/pharmacology , Analgesics/pharmacology , Antidepressive Agents/pharmacology , Behavior, Animal/drug effects , Bupropion/pharmacology , Depression/drug therapy , Fluoxetine/pharmacology , Hyperalgesia/drug therapy , Organoselenium Compounds/pharmacology , Sciatic Nerve/drug effects , Sciatica/drug therapy , Animals , Depression/physiopathology , Depression/psychology , Disease Models, Animal , Hyperalgesia/physiopathology , Hyperalgesia/psychology , Ligation , Male , Mice , Motor Activity/drug effects , Pain Measurement , Sciatic Nerve/physiopathology , Sciatic Nerve/surgery , Sciatica/physiopathology , Sciatica/psychology , Swimming , Time FactorsABSTRACT
UNLABELLED: It is well known that adenine-based purines exert multiple effects on pain transmission. Less attention has been given, however, to the antinociceptive effects of guanine-based purines. The aim of this study was to investigate the effects of intraperitoneal administration of guanosine on a rat model of peripheral mononeuropathy. Additionally, investigation of the mechanism of action of guanosine, its general toxicity and measurements of central nervous system purine levels were performed. Rats received an intraperitoneal administration of vehicle (0.1 mM NaOH) or guanosine (up to 120 mg.kg(-1)) in an acute or chronic regimen. Guanosine significantly reduced thermal hyperalgesia on the ipsilateral side of the sciatic nerve ligation. Additionally, guanosine prevented locomotor deficits and body weight loss induced by the mononeuropathy. Acute systemic administration of guanosine caused an approximately 11-fold increase on central nervous system guanosine levels, but this effect was not observed after chronic treatment. Chronic guanosine administration prevented the increase on cortical glutamate uptake but not the decrease in spinal cord glutamate uptake induced by the mononeuropathy. No significant general toxicity was observed after chronic exposure to guanosine. This study provides new evidence on the mechanism of action of guanine-based purines, with guanosine presenting antinociceptive effects against a chronic pain model. PERSPECTIVE: This study provides a new role for guanosine: chronic pain modulation. Guanosine presents as a new target for future drug development and might be useful for treatment of neuropathic pain.
Subject(s)
Analgesics/therapeutic use , Guanosine/therapeutic use , Hyperalgesia/etiology , Hyperalgesia/prevention & control , Sciatica/complications , Analgesics/cerebrospinal fluid , Analgesics/pharmacology , Animals , Central Nervous System/drug effects , Central Nervous System/metabolism , Chromatography, High Pressure Liquid/methods , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Routes , Exploratory Behavior/drug effects , Glutamic Acid/metabolism , Guanosine/cerebrospinal fluid , Guanosine/pharmacology , Hyperalgesia/pathology , Male , Movement Disorders/etiology , Movement Disorders/prevention & control , Pain Measurement , Pain Threshold/drug effects , Rats , Rats, Wistar , Sciatica/drug therapy , Statistics, Nonparametric , Time FactorsABSTRACT
Preemptive analgesia inhibits the progression of pain caused by surgical lesions. To analyze the effect of lidocaine on postoperative pain relief, we performed compression of the right sciatic nerve in Wistar rats and observed the differences on behavior between the group that received lidocaine and the group that was not treated with the local anesthetics pre-operatively. Group 1 was not operated (control); group 2 underwent the sciatic nerve ligature without lidocaine; group 3, underwent surgery with previous local infiltration of lidocaine. Group 2 showed significantly longer scratching times with a peak on day 14 post-operative (p=0.0005) and reduction in the latency to both noxious (p=0.003) and non-noxious (p=0.004) thermal stimulus. Group 3 presented significantly shorter scratching times (p=0.004) and longer latency times when compared to Group 2. Preemptive use of lidocaine 2 percent can potentially reduce the postoperative neuropathic pain associated with sciatic nerve compression.
A analgesia preemptiva inibe a progressão da dor causada por lesão cirúrgica. Para analisar o efeito da lidocaína na diminuição da dor pós-operatória, submetemos ratos Wistar a compressão cirúrgica do nervo ciático e observamos diferenças em alguns padrões de comportamento entre o grupo tratado com lidocaína pré-operatória e o grupo não-tratado com o anestésico local. O grupo 1 não foi operado (controle); o grupo 2, submetido a ligadura do nervo ciático sem lidocaína, apresentou significativo aumento do tempo de coçar-se com um pico no 14º pós-operatório (p=0.0005) e redução na latência para os estímulos térmicos nocivo (p=0.003) e não-nocivo (p=0.004); o grupo 3, operado com a droga preemptiva, demonstrou significativo decréscimo no tempo de coçar-se (p=0.004) e maiores tempos de latência quando comparados aos do grupo 2. O uso preemptivo da lidocaína 2 por cento pode, potencialmente, reduzir a dor neuropática pós-operatória associada à compressão do nervo ciático.
Subject(s)
Animals , Rats , Anesthetics, Local/therapeutic use , Lidocaine/therapeutic use , Pain, Postoperative/prevention & control , Sciatic Nerve/injuries , Sciatica/drug therapy , Chronic Disease , Disease Models, Animal , Rats, Wistar , Sciatic Nerve/surgery , Time FactorsABSTRACT
Preemptive analgesia inhibits the progression of pain caused by surgical lesions. To analyze the effect of lidocaine on postoperative pain relief, we performed compression of the right sciatic nerve in Wistar rats and observed the differences on behavior between the group that received lidocaine and the group that was not treated with the local anesthetics pre-operatively. Group 1 was not operated (control); group 2 underwent the sciatic nerve ligature without lidocaine; group 3, underwent surgery with previous local infiltration of lidocaine. Group 2 showed significantly longer scratching times with a peak on day 14 post-operative (p=0.0005) and reduction in the latency to both noxious (p=0.003) and non-noxious (p=0.004) thermal stimulus. Group 3 presented significantly shorter scratching times (p=0.004) and longer latency times when compared to Group 2. Preemptive use of lidocaine 2% can potentially reduce the postoperative neuropathic pain associated with sciatic nerve compression.
Subject(s)
Anesthetics, Local/therapeutic use , Lidocaine/therapeutic use , Pain, Postoperative/prevention & control , Sciatic Nerve/injuries , Sciatica/drug therapy , Animals , Chronic Disease , Disease Models, Animal , Rats , Rats, Wistar , Sciatic Nerve/surgery , Time FactorsABSTRACT
Lumbosciatica is a common condition which is associated with significant pain and disability. The aim of the present study was to examine the efficacy of interlaminar epidural corticosteroid infiltration in the treatment of lumbosciatic pain. We evaluated retrospectively sixty patients with lumbosciatic pain that a sequential interlaminar epidural administration of 40 mg methylprednisolone in 7 mL bupivacaine 0.25 percent was administered. Each patient was interviewed and asked about the pain according to visual analogue scale (VAS) and the level of disability according to World Health Organization previously of the epidural corticosteroid infiltration and, 1 and, 6 months after starting therapy. Independently of the initial VAS value, all patients decreased their pain score after one and six months of follow-up (p<0.05). However, only the patients with a low grade of disability showed an improvement after the treatment (p<0.05). No side effects were reported after epidural corticosteroid injections. In conclusion, interlaminar epidural corticosteroid injection in association with local anesthetic may be useful, at least for six months, as additional therapy of the conservative management of lumbosciatic pain.
A lombociatalgia é condição clínica associada à dor intensa e alterações funcionais. O objetivo do presente estudo foi examinar a eficácia da infiltração de corticóide pela via epidural interlaminar no tratamento da dor da lombociatalgia. Foram avaliados, retrospectivamente, sessenta pacientes com lombociatalgia que foram submetidos à administração epidural interlaminar, em sequência, de 40 mg de metilprednisolona e 7 mL de bupivacaína a 0,25 por cento. Os pacientes foram avaliados em relação à dor de acordo com a escala visual analógica (EVA) e o grau de comprometimento funcional de acordo com a Organização Mundial de Saúde antes e, uma e, seis meses após o início do tratamento. Independentemente do valor inicial da EVA, todos os pacientes diminuíram o escore de dor após um e, seis meses de acompanhamento (p<0.05). Entretanto, apenas os pacientes com baixo grau de comprometimento funcional apresentaram melhora após o tratamento (p<0.05). Não foram observados efeitos colaterais após as injeções de corticóide epidural. Concluindo, a injeção epidural interlaminar de corticóide em associação com anestésico local pode ser benéfico, por pelo menos seis meses, como terapia coadjuvante no tratamento conservador da dor da lombociatalgia.
Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Anesthetics, Local/administration & dosage , Bupivacaine/administration & dosage , Glucocorticoids/administration & dosage , Low Back Pain/drug therapy , Methylprednisolone/administration & dosage , Sciatica/drug therapy , Drug Therapy, Combination , Follow-Up Studies , Retrospective Studies , Severity of Illness Index , Treatment OutcomeABSTRACT
Lumbosciatica is a common condition which is associated with significant pain and disability. The aim of the present study was to examine the efficacy of interlaminar epidural corticosteroid infiltration in the treatment of lumbosciatic pain. We evaluated retrospectively sixty patients with lumbosciatic pain that a sequential interlaminar epidural administration of 40 mg methylprednisolone in 7 mL bupivacaine 0.25% was administered. Each patient was interviewed and asked about the pain according to visual analogue scale (VAS) and the level of disability according to World Health Organization previously of the epidural corticosteroid infiltration and, 1 and, 6 months after starting therapy. Independently of the initial VAS value, all patients decreased their pain score after one and six months of follow-up (p<0.05). However, only the patients with a low grade of disability showed an improvement after the treatment (p<0.05). No side effects were reported after epidural corticosteroid injections. In conclusion, interlaminar epidural corticosteroid injection in association with local anesthetic may be useful, at least for six months, as additional therapy of the conservative management of lumbosciatic pain.
Subject(s)
Anesthetics, Local/administration & dosage , Bupivacaine/administration & dosage , Glucocorticoids/administration & dosage , Low Back Pain/drug therapy , Methylprednisolone/administration & dosage , Sciatica/drug therapy , Adult , Aged , Aged, 80 and over , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Male , Middle Aged , Retrospective Studies , Severity of Illness Index , Treatment OutcomeABSTRACT
This study investigated the anti-allodynic and anti-oedematogenic effects of the hexanic extract, lignan-rich fraction and purified lignans from a plant used in the traditional medicine, Phyllanthus amarus, in the inflammatory and neuropathic models of nociception. The hexanic extract inhibited the allodynia and the oedema induced by the intraplantar injection of complete Freund's adjuvant (CFA). The inhibition observed was 76 +/- 7% (ipsilateral paw), 64 +/- 7% (contralateral paw), and 41 +/- 2% (oedema). Otherwise, the lignan-rich fraction or the pure lignans did not affect CFA-induced allodynia. Administered chronically, the lignan fraction reduced CFA-induced paw oedema (39 +/- 9%). When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%). The anti-allodynic effects of hexanic extract of P. amarus seem not to be associated with the impairment of motor co-ordination or with the development of tolerance. Finally, the treatment with hexanic extract inhibited the increase of myeloperoxidase activity, either following intraplantar injection of CFA or after sciatic nerve injury. It is concluded that, apart from its anti-inflammatory actions, which are probably linked to the presence of lignans, another as yet unidentified active principle(s) present in the hexanic extract of P. amarus produces pronounced anti-allodynia in two models of inflammatory and neuropathic pain. Considering that few drugs are currently available for the treatment of chronic pain, especially of the neuropathic type, the present results may have clinical relevance and open new possibilities for the development of new anti-allodynic drugs.
Subject(s)
Amines , Analgesics/pharmacology , Anti-Inflammatory Agents/pharmacology , Cyclohexanecarboxylic Acids , Edema/prevention & control , Inflammation/drug therapy , Pain/drug therapy , Peripheral Nervous System Diseases/drug therapy , Phyllanthus/chemistry , gamma-Aminobutyric Acid , Acetates/pharmacology , Animals , Edema/chemically induced , Enzyme Inhibitors/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Freund's Adjuvant , Gabapentin , Hexanes , Inflammation/chemically induced , Ligation , Lignans/isolation & purification , Lignans/pharmacology , Male , Mice , Motor Activity/drug effects , Neutrophil Infiltration/drug effects , Pain/chemically induced , Peripheral Nervous System Diseases/chemically induced , Peroxidase/antagonists & inhibitors , Peroxidase/metabolism , Physical Stimulation , Plant Extracts/pharmacology , Psychomotor Performance/drug effects , Sciatica/drug therapy , Sciatica/pathology , SolventsABSTRACT
Se hace un análisis prospectivos de 141 pacientes portadores de un síndrome radicular lumbar, que fueron incluidos en un grupo de estudio con criterios de inclusión estrictos a los cuales se les administró una dosis única de 80 mg de metilprednisolona en el espacio epidural con técnica interlaminar por un anestesista calificado. El seguimiento mínimo fue de 6 meses con una media de 3 años. La edad promedio de los pacientes fue de 46 años (15-63). Las hernias discales fueron clasificados de acuerdo al: nivel, localización y tamaño. La efectividad del procedimiento fue evaluada en términos de desaparición del cuadro radicular y del test de extensión con pierna extendida (TEPE). En un periodo de seguimiento a corto plazo, el 39 por ciento de los pacientes experimentaron un alivio completo de la sintomalogía post infiltración, pero después de un seguimiento a mayor plazo (6 meses), este porcentaje disminuyó a un 26 por ciento del total de 141 pacientes que fueron incluidos en este estudio. Se obtuvieron mejores resultados con las hernias discales; las hernias de situación medial tienen mejores resultados en comparción con otras localizaciones (51 por ciento) y finalmente las hernias tipo A (pequeñas) responden mejor (43 por ciento) en relación con otros tamaños. Las hernias discales LA-L5 del tipo A y en situación medial, tienen en general los mejores resultados. Los peores resultados se obtuvieron con hernias del nivel L3-L4 y definitivamente ningún paciente portador de hernias del tamaño C respondió adecuadamente al procedimiento. Las complicaciones del método fueron mínimas
Subject(s)
Humans , Female , Male , Adolescent , Adult , Middle Aged , Sciatica/drug therapy , Low Back Pain/drug therapy , Sciatica/etiology , Low Back Pain/etiology , Injections, Epidural , Intervertebral Disc Displacement/complications , Methylprednisolone/administration & dosage , Methylprednisolone/pharmacology , Prospective Studies , Treatment OutcomeABSTRACT
Através de um estudo duplo-cego e comparativo foi avaliada a eficácia e a tolerância de dois antiinflamatórios näo hormonais, o cetoprofeno (100 mg) e o diclofenac (75 mg), por via parenteral, em 60 pacientes portadores de lombociatalgia aguda. As medicaçöes foram administradas em duas doses diárias e as avaliaçöes feitas diariamente por um período de sete dias, onde, através de escalas de dor, índices de Schobber e de Ritchie e manobra de Lasègue, se caracterizou a presença e intensidade da dor e da síndrome raquidiana. A eficácia e a tolerância das duas drogas foram semelhantes, sendo encontrada melhora significativa a partir do segundo dia de tratamento e os efeitos colaterais mais freqüentes relacionados ao trato gastrointestinal, porém de intensidade leve a moderada